Key Takeaways
- • Dassault Systèmes has agreed to acquire ArisGlobal, an AI-driven software provider serving the life sciences industry, from Nordic Capital for up to $2 billion in an all-cash transaction announced July 23, 2026.
- • The deal positions Dassault to expand its footprint in life sciences software and AI capabilities, complementing its existing portfolio of industry solutions.
- • Kirkland & Ellis and Sullivan & Cromwell served as legal counsel on the transaction, reflecting the deal's scale and complexity.
- • ArisGlobal's AI-focused platform addresses regulatory compliance, clinical trial management, and operational efficiency—critical functions for pharmaceutical and biotech companies navigating complex regulatory environments.
- • The acquisition represents significant investor exit for Nordic Capital and validates the strategic value of specialized AI software in regulated life sciences markets.
Summary
Dassault Systèmes announced on Thursday, July 23, 2026, that it has agreed to acquire ArisGlobal, a privately held software company specializing in AI-driven solutions for life sciences companies, from private equity firm Nordic Capital. The transaction is valued at up to $2 billion and structured as an all-cash purchase, according to statements from both parties.
ArisGlobal provides software solutions designed specifically for pharmaceutical, biotechnology, and medical device companies. The platform leverages artificial intelligence to streamline critical operational functions including regulatory compliance, clinical trial management, pharmacovigilance, and quality assurance—areas where precision and regulatory adherence are paramount. By acquiring ArisGlobal, Dassault gains direct access to specialized domain expertise and established customer relationships within the highly regulated life sciences sector.
The transaction was facilitated by two prominent global law firms: Kirkland & Ellis and Sullivan & Cromwell provided legal counsel on the deal. The involvement of these top-tier advisors underscores the transaction's complexity and the significant capital deployed. Nordic Capital, which has held ArisGlobal as part of its investment portfolio, will realize a substantial exit through the sale.
The acquisition aligns with Dassault Systèmes' broader strategy to strengthen its position in life sciences and expand its AI capabilities. The company has increasingly focused on vertical solutions that address specific industry pain points, and ArisGlobal's specialized platform complements existing offerings in the life sciences technology ecosystem. For institutional investors monitoring M&A activity in software and AI, this transaction reflects sustained appetite for specialized, mission-critical software providers serving regulated industries where switching costs and customer stickiness remain high.
ArisGlobal provides software solutions designed specifically for pharmaceutical, biotechnology, and medical device companies. The platform leverages artificial intelligence to streamline critical operational functions including regulatory compliance, clinical trial management, pharmacovigilance, and quality assurance—areas where precision and regulatory adherence are paramount. By acquiring ArisGlobal, Dassault gains direct access to specialized domain expertise and established customer relationships within the highly regulated life sciences sector.
The transaction was facilitated by two prominent global law firms: Kirkland & Ellis and Sullivan & Cromwell provided legal counsel on the deal. The involvement of these top-tier advisors underscores the transaction's complexity and the significant capital deployed. Nordic Capital, which has held ArisGlobal as part of its investment portfolio, will realize a substantial exit through the sale.
The acquisition aligns with Dassault Systèmes' broader strategy to strengthen its position in life sciences and expand its AI capabilities. The company has increasingly focused on vertical solutions that address specific industry pain points, and ArisGlobal's specialized platform complements existing offerings in the life sciences technology ecosystem. For institutional investors monitoring M&A activity in software and AI, this transaction reflects sustained appetite for specialized, mission-critical software providers serving regulated industries where switching costs and customer stickiness remain high.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.